Hakim C.
- Country
- France
- Department
- Unité Clinique
Research Overview
- A Phase I Study to Evaluate the Safety and Tolerability of Lu AH70212 and Lu AH69593 in Healthy Adults for the Treatment of Narcolepsy
- A Randomized, Open-Label, Single-Center Study to Evaluate the Bioequivalence of Lanifibranor in Patients with Non-alcoholic Steatohepatitis
- Phase 1/2a Evaluation of SPK002 Safety, Pharmacokinetics, and Neutralizing Activity for COVID-19 Prophylaxis in Healthy and Immunocompromised Subjects
Data & Insights
Has run more than one trial at 1 of 2 partner sites.
Specializations
Infectious Disease Research
The investigator specializes in studying pre-exposure prophylaxis interventions for viral infections, with particular emphasis on COVID-19 prevention. Their work extends to both healthy populations and immunocompromised individuals, addressing critical preventive care needs.
- COVID-19 Prophylaxis
- Immunocompromised Patient Care
- Preventive Medicine
Hepatology Studies
This researcher focuses on hepatic impairment investigations, examining therapeutic responses across varying degrees of liver function. Their work encompasses the study of oral medications in patients with different levels of hepatic function.
- Liver Function Assessment
- Hepatic Drug Metabolism
- Chronic Liver Conditions
Clinical Pharmacology
The investigator conducts comprehensive studies in clinical pharmacology, focusing on drug interactions and therapeutic responses. Their research includes detailed analysis of pharmacokinetics and pharmacodynamics in healthy individuals.
- Drug Safety Assessment
- Therapeutic Drug Monitoring
- Drug Interaction Studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.